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T2 is a transmembrane receptor belonging to the IL (interleukin)-1 receptor family implicated in inflammation and immunity. [1] [2] [3] [4] ST2 binds IL-33 in response to cardiac injury, an interaction that results in antihypertrophic, antifibrotic, and antiapoptotic effects. 5, 6 A truncated soluble form of ST2 (sST2) competes with the membrane-bound form for binding with IL-33. Elevated levels of sST2 are associated with the presence and severity of adverse cardiac remodeling and fibrosis. In animal models, sacubitril/valsartan has been shown to improve cardiac remodeling and reduce fibrosis after myocardial infarction (MI). 7, 8 Experimentally, administration of sST2 antagonizes the benefits of IL-33 and results in a deleterious phenotype marked by myocardial hypertrophy, ventricular dilatation, and reduced contractility. 6 Both cardiac fibroblasts and cardiomyocytes express IL-33 and sST2. 9 Elevations in sST2 have been observed in patients after acute MI, acute heart failure (HF), and chronic HF. [10] [11] [12] [13] [14] [15] [16] [17] [18] sST2 has emerged as a powerful prognostic biomarker in chronic HF with a reduced ejection fraction (HFrEF). [18] [19] [20] Moreover, changes in sST2 values also have prognostic value in chronic HF. 21 However, in HFrEF, the predictive value of sST2 and changes in sST2 have not been evaluated in a model that includes both currently available biomarkers NT-proBNP (N-terminal pro-B-type natriuretic peptide) and hs-TnT (high-sensitivity cardiac troponin T), and in a trial in which the pharmacological intervention had a major clinical impact.
In the PARADIGM-HF trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), sacubitril/ valsartan (an angiotensin receptor/neprilysin inhibitor) significantly reduced hospitalization for HF and cardiovascular as well as all-cause mortality. 22 Sacubitril/valsartan simultaneously blocks the renin-angiotensin system and enhances endogenous compensatory vasoactive peptides including natriuretic peptides. 23 In addition to reducing levels of NT-proBNP, 24, 25 sacubitril/valsartan reduced hs-TnT, a marker of myocardial injury and known independent predictor of prognosis in HF. 22, 24 The objectives of this study were (1) to examine the effects of treatment with sacubitril/valsartan, compared with enalapril, on circulating levels of sST2 over time in the PARADIGM-HF trial; (2) to assess whether baseline and change from baseline, levels of sST2 were independently associated with the occurrence of the primary outcome (cardiovascular death or HF hospitalization), hospitalizations for HF, and cardiovascular death in PAR-ADIGM-HF, in a model in which both NT-proBNP and hs-TnT are included; and (3) to determine the prognostic utility of various published and proposed partition values relating baseline and change from baseline values of sST2 to clinical outcomes.
METHODS

Study Design and Procedures
The study design and procedures for the PARADIGM-HF trial have been previously described. 22, 26 The institutional review board of each of the 1043 participating institutions (in 47 countries) approved the protocol which included the examination of biomarkers, and all patients gave written, informed consent. Patients had New York Heart Association class II to IV symptoms, an EF of ≤40% (changed to ≤35% by amendment), and a BNP ≥150 pg/mL (or NT-proBNP ≥600 pg/mL) or, if they had been hospitalized for HF within the previous 12 months, a BNP of at least 100 pg per milliliter (or a NT-proBNP ≥400 pg per milliliter). 22, 26 Patients taking any dose of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker were considered for enrollment but were required to tolerate the equivalent of enalapril 10 mg daily for at least 4 weeks before screening along with stable doses of a β-blocker (unless contraindicated or not tolerated) and a mineralocorticoid receptor antagonist (if indicated). Among the exclusion criteria, patients were not eligible for the trial if they had a history of intolerance of an angiotensin-converting enzyme inhibitor or angiotensin receptor blockers. 22, 26 Serum sST2 measurements were obtained at baseline (before the run-in period), at 1 month and at 8 months after randomization. Samples were collected at about the same morning hour for each visit with biomarker sampling (subjects seated for 10-15 minutes) and were stored locally at −20°C for 1 month, then transferred on dry ice to the central laboratory for storage at −80°C.
Patient Population
Only a subset of the PARADIGM-HF clinical trial centers participated in the biomarkers ancillary studies. Specifically, for logistical reasons, centers in Asia/South Pacific and in
WHAT IS NEW?
• Plasma biomarkers have diagnostic and prognostic value and provide targets for the development of novel therapies in patients with heart failure. For example, changes in soluble ST2 (sST2) are associated with cardiac remodeling, fibrosis, and outcomes. • In the PARADIGM-HF trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), sacubitril/ valsartan, compared with enalapril, was associated with greater reductions and less increases in sST2. Baseline sST2 levels were independent predictors of clinical outcomes; associations between baseline sST2 and outcomes were linear, suggesting that no specific threshold would indicate a greater or lesser risk.
WHAT ARE THE CLINICAL IMPLICATIONS?
• Change in sST2 from baseline to 1 month was independently associated with a significant change in the risk of subsequent outcomes. Plasma NT-proBNP and hs-TnT were measured by using the Roche Elecsys proBNP (Roche Diagnostics, Indianapolis, IN) and the fifth generation high-sensitivity Troponin T assay (Roche Diagnostics GmbH, Germany), respectively. 24 Renal function was evaluated by estimating glomerular filtration rate, using the modification of diet in renal disease equation.
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Statistical Analysis
Baseline characteristics of PARADIGM-HF patients with and without a sST2 measurement are summarized using mean±SD, median (interquartile range), or frequency and percentages, as appropriate, with comparisons between the 2 groups conducted using t test, Wilcoxon rank-sum test, and Pearson χ 2 test, respectively. To identify the most significant multivariable correlates of baseline sST2 values from among the other patient-level covariates collected at baseline, linear regression using log-transformed baseline sST2 with forward stepwise selection were identified using threshold P value=0.05. sST2 values at baseline, month 1, and month 8 postrandomization and corresponding changes from baseline are summarized for each treatment group using median (interquartile range), using quantile regression, adjusting for the baseline value, to compare the absolute changes between treatment groups. Similarly, because of the right-skewed nature of sST2 values, summary statistics were presented using geometric means. The effect of randomized treatment on sST2 changes from baseline was assessed using linear regression with logtransformed sST2 values as the outcome and adjusted for log-transformed baseline sST2, with the resulting parameter estimate representing the relative change in sST2 attributable to sacubitril/valsartan. As a specific threshold of 35 ng/mL for sST2 has been suggested as clinically relevant, the proportions of patients with sST2 levels exceeding this threshold at each of 3 separate time points (ie, baseline, 1 month, 8 months) was reported for each treatment group and compared using unadjusted logistic regression. 29, 30 Because of uncertainty surrounding the specific threshold to be used for sST2, we performed sensitivity analyses based on lower thresholds of 32, 30, and 25 ng/mL. Because little is known about the magnitude of within-patient change after initiating therapy, we report and compare the proportions of patients in each treatment group with sST2 increases or decreases from baseline of specific magnitudes. Because of skewed distribution of sST2 and the uncertainty about assumptions of linearity, the relationships between baseline sST2 and incidence rates of subsequent clinical outcomes (hospitalization for HF, cardiovascular death, and the primary composite of these 2 outcomes) were assessed using Poisson regression models with sST2 modeled using restricted cubic spline with 3 knots in models adjusted for baseline characteristics listed in Table 1 : age, sex, geographic region, body mass index, New York Heart Association class, left ventricular EF, prior HF hospitalization, hypertension, diabetes mellitus, ischemic cause of HF, prior MI, atrial fibrillation, heart rate, systolic blood pressure, creatinine, prior stroke, implantable cardioverter defibrillator, cardiac resynchronization therapy, prior use of an angiotensin-converting enzyme inhibitor, prior use of an angiotensin receptor blocker, diuretics, β-blockers, digoxin, mineralocorticoid receptor antagonist, log (NT-proBNP), log (BNP), log (hs-TnT); and randomized treatment (enalapril or sacubitril/valsartan). Similarly, adjusted hazard ratios were produced using Cox proportional hazards models using both untransformed and log-transformed baseline sST2 values. Landmark analyses of proportional changes in sST2 from baseline to month 1 versus subsequent clinical outcomes were assessed using adjusted Cox proportional hazards models. These models included adjustments for changes in BNP, NT-proBNP, and hs-TnT. sST2 effect modification by randomized therapy was assessed via interaction terms for all clinical outcomes. Harrell C statistics for the following models of time-to-event outcomes (Table II in the Data Supplement) were calculated: (1) analysis without any of the 4 biomarkers, (2) analysis with each of the 4 biomarkers individually, and (3) analysis with all 4 biomarkers. Patients were then categorized according to their baseline values of both sST2 and NT-proBNP, using thresholds of 32 ng/mL and 1000 pg/mL, respectively, to define 4 groups of patients as having low/low, low/high, high/low, or high/ high biomarker levels. The relationship between these groupings and the primary outcome was assessed using Cox proportional hazards models with and without adjustment for baseline covariates. To examine the dose-dependent relationship between exposure to sacubitril/valsartan and changes in sST2, linear regression was performed to describe the relationship between total cumulative exposure to sacubitril/valsartan from baseline to 8-month postrandomization and the resulting change from baseline of sST2 observed at month 8. To assess whether the relationships between baseline sST2 and the primary outcome were modified by baseline EF, we estimated the relationship between sST2 and incidence of the primary outcome separately for each of 3 subgroups of patients defined by their baseline EF (<28%, 28% to 33%, >33%) using restricted cubic splines. The resulting interaction P value was obtained from a likelihood ratio test. The effects of EF on the relationship between baseline sST2 and the primary outcome was examined. The effect of variation in cumulative dose exposure to sacubitril/valsartan during an 8-month time frame after randomization on the correlation between sST2 change from baseline to month 8 and the primary outcome was examined. All analyses were conducted using STATA version 14 (College Station, TX) and P values <0.05 were considered statistically significant. No adjustments were made for multiple comparisons. The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
RESULTS
The characteristics of the study population are presented in Table 1 . Patients who participated in the sST2 biomarker study (n=2002) and patients that did not participate in the sST2 biomarker study (n=6397) had several statistically significant differences; all presented analyses were adjusted for each of the characteristics listed in Table 1 that differed significantly between the 2 groups. Figure 1 shows the distribution of sST2 levels at baseline. The median (interquartile range) sST2 baseline level was 32.2 (25.4-41.5) ng/mL. The strongest independent predictors of higher baseline sST2 levels were higher NT-proBNP, male sex, and a history of atrial fibrillation (Table 2) . Baseline sST2 levels were positively correlated with hs-TnT levels, with a correlation coefficient of +0.22 (P<0.001), and with NT-proBNP levels (correlation coefficient +0.26, P<0.001; Figure I in the Data Supplement).
Compared with enalapril, treatment with sacubitril/ valsartan reduced levels of sST2 (Table 3 ) resulting in statistically significant treatment differences at both 1 and 8 months (P<0.001 for the difference in geometric means). When evaluating % changes from baseline in sST2 levels, sacubitril/valsartan (LCZ696) was associated with more reductions and fewer increases in sST2 levels than enalapril at both 1 and 8 months, regardless of the threshold used ( Figure II in the Data Supplement).
At baseline, the proportion of patients with sST2>35 ng/mL was similar in the sacubitril/valsartan and enala- ACE inhibitor indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate; HF, heart failure; HHF, heart failure hospitalization; hs-TnT, high-sensitivity cardiac troponin T; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; SBP, systolic blood pressure; and sST2, soluble ST2. 
34).
As shown in Table 4 , in comparison to patients treated with enalapril, a lower proportion of patients treated with sacubitril/valsartan had sST2 levels higher than the (US Food and Drug Administration approved) 35 ng/mL threshold or higher than the median of 32 ng/ mL at both month 1 and month 8 after randomization. Using lower absolute sST2 thresholds (Table 4) resulted in similar findings.
Baseline sST2 Levels and Clinical Outcomes
After adjusting for the other predictors of outcome in PARADIGM-HF, including NT-proBNP, and hs-TnT, baseline sST2 remained an independent predictor of the primary composite outcome of cardiovascular death or HF hospitalization, of HF hospitalization, and of cardiovascular death; as illustrated on Figure 2 and Table 5 . The risk related to higher sST2 levels was approximately linear for the 3 outcomes evaluated (no evidence of nonlinearity in any of the 3 adjusted models, all P values >0.30). Harrell C statistics (Table II in the Data Supplement) showed that each of the 4 biomarkers (sST2, BNP, NT-proBNP, hsTroponin) individually improved the ability to discriminate between patients with versus without clinical events, with the greatest improvement occurring when all 4 biomarkers were used in combination. Figure VI in the Data Supplement shows the unadjusted relationship between sST2 and primary outcome for each EF subgroup. EF was not found to modify the relationship between baseline sST2 and the primary outcome (P for interaction between EF category and sST2 was 0.76 without adjustment and 0.96 after adjustment for other baseline covariates). Figure 3 illustrates changes in sST2 concentration from baseline to 1-month postrandomization in relation to subsequent clinical outcomes, after adjusting for baseline sST2 concentration, clinical covariates, hs-TnT, NT-proBNP, and randomized treatment. As shown on these graphs, increases in sST2 were associated with worse outcomes, whereas decreases were associated with better outcomes, whether considering the primary outcome (top), HF hospitalization (center), or cardiovascular death (lower panel). There was no evidence of nonlinearity or interaction with randomized treatment (P>0.15 for all).
sST2 Changes From Baseline Versus Clinical Outcomes
Four additional models were used to examine the relationship between change in sST2 from baseline to 1 month and the primary outcome. In addition to the model described above, the models were subsequently adjusted for sequential additions of baseline BNP, change in BNP, change in NT-proBNP, and change in hsTnT ( Figure III in the Data Supplement). After adjustment for all 4 biomarkers at both baseline and 1-month follow-up, the combined association between paired sST2 measures and the primary outcome was comparable to that of paired NT-proBNP measures and stronger than paired BNP measures (Table III in the Data Supplement).
The relationship between baseline values of both sST2 and NT-proBNP with the primary outcome using a categorical analysis was examined ( Figure IV in the Data Supplement). The unadjusted hazard ratios for each group (using the low NT-proBNP / low sST2 group as reference) are low NT-proBNP / high sST2=1.28, high NT-proBNP / low sST2=1.93, high NT-proBNP / high sST2=2.96. After adjustment for other baseline characteristics and treatment, the hazard ratios were similar: low NT-proBNP / high sST2=1.24, high NT-proBNP / low sST2=1.86, high NT-proBNP / high sST2=2.72. The effect of variation in cumulative dose exposure to sacubitril/valsartan during an 8-month time frame after randomization on the correlation between sST2 change from baseline to month 8 and the primary outcome was examined (Figure V in the Data Supplement). The bar graphs embedded in this figure represent the number of subjects with a given dose exposure. All subjects underwent a run-in period during which they received enalapril for 2 to 4 weeks followed by sacubitril/valsartan for 3 to 6 weeks. Therefore, the first 2 bars represent patients who were randomized to enalapril after the run-in period who were exposed to only a small cumulative dose of sacubitril/valsartan. The higher the cumulative dose of sacubitril/valsartan, the greater the percent decrease in sST2.
DISCUSSION
In this study of ≈2000 patients with HFrEF, treatment with sacubitril/valsartan resulted in further reductions in sST2 levels when compared with enalapril. Baseline levels of sST2 had independent prognostic utility both at the US Food and Drug Administration approved partition value of 35 ng/mL and using other partition values; even when other variables known to be associated with outcomes, including NT-proBNP and hsTnT, were included in the analyses. We observed no specific sST2 threshold that identified a higher risk of the primary outcome (cardiovascular death or HF hospitalization), hospitalizations for HF, and cardiovascular death (linear relationships). Changes in sST2 level from baseline to 1 month were associated with the subsequent risk of major outcomes, even when corrected for baseline sST2 concentration, clinical covariates, NT-proBNP, hs-TnT, and randomized treatment.
sST2 Concentrations in PARADIGM-HF and Changes With Therapy
In PARADIGM-HF, median baseline sST2 levels were 32.2 (25.4-41.5) ng/mL, with a majority (76%) of patients in PARADIGM-HF having levels above the normal threshold. 27 Forty-one percent of participants had values above the currently approved prognostic threshold of 35 ng/mL. Of note, 90% to 95% of normal individuals have levels below this threshold. 29, 31 Baseline sST2 levels were generally correlated with factors reflecting severity of HF, and, as demonstrated previ- ously. Although statistically significant, sST2 was only weakly correlated with NT-proBNP and hs-TnT levels; suggesting that although all 3 of these biomarkers are correlated with severity of disease there exists significant differences in their activation from one individual to another. Sacubitril/valsartan reduced sST2 levels at both 1 and 8 months, whereas enalapril did not. This was found whether sST2 was evaluated as a continuous variable, or whether it was evaluated as the percentage of patients above or below the FDA threshold of 35 ng/ mL or any other threshold evaluated. This is the first time that a reduction in sST2 levels over time has been documented in a trial in which an intervention has been demonstrated as beneficial which, combined with previous studies, strengthens the case for the use of sST2 as a prognostic marker.
Baseline sST2 and Clinical Outcomes
In the present study, there was a linear correlation between baseline sST2 levels and the primary outcome (cardiovascular death or HF hospitalization), hospitalizations for HF, and cardiovascular death. This relationship was independent of clinical variables and both NT-proB-NP and hs-TnT suggesting that sST2 levels are associated with risks independent of those generally reflected by these variables and supporting a role for measuring sST2 when evaluating risk. Prior studies have shown that baseline sST2 can add prognostic value on top of clinical models of risk prediction, that in a few studies included NT-proBNP or hs-TnT, in patients with chronic HF 14, 30, [32] [33] [34] [35] or in an acute HF setting. 36 However, these associations were not observed in all studies addressing this issue, and a linear relationship was never described. Prior studies identified thresholds above which prognosis was worse, and thresholds in sST2 associated with progression of cardiac dysfunction in patients with HF. Although we also found that baseline thresholds of sST2 were predictive of outcome, because of the linear relationship we found between sST2 levels and outcomes, our findings suggest that specific thresholds may not be the ideal approach to use when relating sST2 concentrations to the risk of clinical outcomes in chronic HFrEF. The predictive value of baseline sST2 levels remained significant when the use of mineralocorticoid receptor The incidence of the primary outcome (heart failure hospitalization [HHF] or cardiovascular [CV] death), of HF hospitalization and of CV death is shown as events per 100 patient-years; according to baseline sST2 levels (ng/mL). Models were adjusted for age, sex, baseline (Bsl) region, body mass index (BMI), New York Heart Association (NYHA), left ventricular ejection fraction (LVEF) bsl, prior heart failure hospitalization (HHF), hypertension, diabetes mellitus, ischemic cause, prior myocardial infarction (MI), atrial fibrillation, Bsl heart rate, Bsl systolic blood pressure (SBP), Bsl creatinine, prior stroke, implantable cardioverter defibrillator (ICD), cardiac resynchronization therapy (CRT), prior use of angiotensin-converting enzyme (ACE inhibitor), prior use of angiotensin receptor blocker (ARB), diuretics, β-blockers (BB), digoxin, mineralocorticoid receptor antagonist (MRA), log (NT-proBNP [N-terminal pro-B-type natriuretic peptide]) and log (hs-TnT [high-sensitivity cardiac troponin T]), and randomized treatment. antagonists at baseline was included in the PARADIGM-HF model (and separately testing for interaction provided similar results). Our study thus provides important additional data about the prognostic value of sST2.
Changes in sST2 and Subsequent Clinical Outcomes
In the present study, changes in sST2 with therapy were linearly correlated with the risk of the primary outcome, hospitalizations for HF, and cardiovascular death, with an increase in sST2 associated with a higher risk, and a decrease in sST2 associated with a lower risk. This association was independent of baseline clinical variables, baseline sST2 levels, NT-proBNP, hs-TnT, and therapy, supporting a role for measuring changes in sST2 when evaluating risk. As with baseline sST2 levels, previous trials have generally explored the impact in changes in sST2 thresholds, whether it be a change in sST2 from ≤35 to >35 ng/ mL during the study 31 or a percent change in sST2, and found an association between these thresholds/threshold changes and clinical outcomes. 34 In PARADIGM-HF, we also found thresholds of changes in sST2 to be predictive of clinical outcomes, however, as the relationship between changes in sST2 and clinical outcomes was linear, as with baseline sST2 levels, our findings suggest that specific thresholds may not be the best approach to use when relating changes in sST2 concentrations to the risk of clinical outcomes in chronic HFrEF.
The lack of interaction between sST2 reduction and treatment group with respect to outcomes suggests that the prognostic value of a change in sST2 is similar in patients taking sacubitril/valsartan and enalapril. However, the current data should not be interpreted as having utility in choosing which patients should receive continued long-term treatment with sacubitril/valsartan versus enalapril or when and if treatment should be terminated. Sacubitril/valsartan reduced the primary event rate compared with enalapril in the overall PARADIGM trial and in the sST2 cohort, and there is no evidence of effect modification by baseline sST2. A sustained reduction in sST2 was significantly more likely with sacubitril/ valsartan than with enalapril.
Study Limitations
For logistical reasons, centers in Asia/South Pacific and in South America did not participate in the biomarkers studies of PARADIGM-HF trial, such that the findings reported here may thus not apply to these populations.
Conclusions
In the PARADIGM-HF trial, treatment with sacubitril/valsartan, in comparison to treatment with enalapril, was associated with greater reductions and less increases in sST2 levels over time. Baseline sST2 levels were independent predictors of clinical outcomes and the associations between baseline sST2 and outcomes were linear, suggesting that no specific threshold would indicate a greater or lesser risk. A change in sST2 from baseline to 1 month was independently associated with a significant change in the risk of subsequent outcomes.
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